Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.

Abstract:

BACKGROUND:Proton pump inhibitors (PPI) are widely used to treat acid-related disorders of the upper gastrointestinal tract. However, large observational studies have raised concerns about PPI-associated adverse events. In recent years, data from next-generation sequencing studies suggested that PPIs affect the composition of the intestinal microbiota, while a balanced gut microbiome is essential for maintaining health. AIM:To review the available evidence from next-generation sequencing studies on the effect of PPIs on the intestinal microbiome and to discuss possible implications of PPI-induced dysbiosis in health and disease. METHODS:A systematic review was conducted following the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. A PubMed query yielded 197 results. 19 publications met the prespecified eligibility criteria. RESULTS:Twelve observational study cohorts with 708 PPI users and 11 interventional cohorts with 180 PPI users were included in the review. In most studies, PPI treatment did not affect microbiological richness and diversity, but was associated with distinct taxonomic alterations: In the upper gastrointestinal tract, PPI users showed overgrowth of orally derived bacteria, mostly Streptococcaceae (findings based on six independent cohorts with 126 PPI users). In faecal samples, PPIs increased multiple taxa from the orders Bacillales (eg, Staphylococcaceae), Lactobacillales (eg, Enterococcaceae, Lactobacillaceae, Streptococcaceae) and Actinomycetales (eg, Actinomycetaceae, Micrococcaceae), the families Pasteurellaceae and Enterobacteriaceae and the genus Veillonella. Taxa decreased by PPIs include Bifidobacteriaceae, Ruminococcaceae, Lachnospiraceae and Mollicutes (findings in faecal samples based on 19 independent cohorts with 790 PPI users). CONCLUSION:PPI use is associated with moderate alterations to upper and distal gut microbiota. The available data suggest that PPI-induced hypochlorhydria facilitates colonization of more distal parts of the digestive tract by upper gastrointestinal microbiota.

journal_name

Aliment Pharmacol Ther

authors

Macke L,Schulz C,Koletzko L,Malfertheiner P

doi

10.1111/apt.15604

subject

Has Abstract

pub_date

2020-03-01 00:00:00

pages

505-526

issue

5

eissn

0269-2813

issn

1365-2036

journal_volume

51

pub_type

杂志文章
  • Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages.

    abstract:BACKGROUND:Obesity is associated with non-alcoholic fatty liver disease (NAFLD), and the patatin-like phospholipase 3 (PNPLA3) rs738409 (Ile148Met, C>G) gene polymorphism is one of the most important genetic determinants of NAFLD. Carriers have been reported to better respond to lifestyle modification. AIM:To investig...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13232

    authors: Mangge H,Baumgartner BG,Zelzer S,Prüller F,Schnedl WJ,Reininghaus EZ,Haybaeck J,Lackner C,Stauber R,Aigner E,Weghuber D

    更新日期:2015-07-01 00:00:00

  • Gastric restitution is inhibited by dexamethasone, which is reversed by hepatocyte growth factor and rebamipide.

    abstract:BACKGROUND:Glucocorticoids have been shown to induce peptic ulcers, especially when co-administered with NSAIDs. Hepatocyte growth factor (HGF) plays a role in gastric ulcer repair, facilitating the restitution of gastric mucosal epithelial cells. HGF expression is induced by PGs in gastric fibroblasts. We hypothesized...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.18.s1.19.x

    authors: Takahashi M,Takada H,Takagi K,Kataoka S,Soma R,Kuwayama H

    更新日期:2003-07-01 00:00:00

  • Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.

    abstract:BACKGROUND:Small intestinal bacterial overgrowth and sugar malabsorption (lactose, fructose, sorbitol) may play a role in irritable bowel syndrome. The lactulose breath test is a reliable and non-invasive test for the diagnosis of small intestinal bacterial overgrowth. The lactose, fructose and sorbitol hydrogen breath...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2005.02493.x

    authors: Nucera G,Gabrielli M,Lupascu A,Lauritano EC,Santoliquido A,Cremonini F,Cammarota G,Tondi P,Pola P,Gasbarrini G,Gasbarrini A

    更新日期:2005-06-01 00:00:00

  • Role of inducible nitric oxide synthase in dextran sulphate sodium-induced colitis.

    abstract:BACKGROUND:Different authors have postulated both toxic and protective effects for nitric oxide (NO) in the pathophysiology of active inflammation. AIM:To examine the role of NO, especially that produced by the inducible form of nitric oxide synthase (iNOS), by investigating the effects of NOS inhibitors and NO donors...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2000.014s1026.x

    authors: Yoshida Y,Iwai A,Itoh K,Tanaka M,Kato S,Hokari R,Miyahara T,Koyama H,Miura S,Kobayashi M

    更新日期:2000-04-01 00:00:00

  • Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients.

    abstract:BACKGROUND:Adalimumab, at an induction dose of 160/80 mg followed by 40 mg every other week is approved for treatment of refractory Crohn's disease (CD) and for patients with loss of response to infliximab. AIM:To evaluate the indications for adalimumab, the proportion of inflammatory bowel disease patients who requir...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03878.x

    authors: Swaminath A,Ullman T,Rosen M,Mayer L,Lichtiger S,Abreu MT

    更新日期:2009-02-01 00:00:00

  • Effect of proton pump inhibition on the gastric volume: assessed by magnetic resonance imaging.

    abstract:BACKGROUND:Proton pump inhibitor (PPI) therapy is known to suppress gastric acid secretion. Thus PPI therapy may decrease gastric volume and gastric contents available for gastro-oesophageal reflux by decreasing acid secretion. AIM:To determine the effect of PPI therapy on the gastric volume after a standard meal. ME...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.03947.x

    authors: Babaei A,Bhargava V,Aalam S,Scadeng M,Mittal RK

    更新日期:2009-04-15 00:00:00

  • A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori.

    abstract:BACKGROUND:One-week proton pump inhibitor-based triple therapies are very popular in the US despite limited US data documenting efficacy. We assessed 1-week proton pump inhibitor triple therapies for Helicobacter pylori, and compared them to dual antibiotic therapies (to assess benefit of omeprazole) and to omeprazole-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1997.00230.x

    authors: Laine L,Frantz JE,Baker A,Neil GA

    更新日期:1997-10-01 00:00:00

  • Review article: inflammatory bowel disease--empowering the patient and improving outcome.

    abstract::Inflammatory bowel disease, in common with most chronic diseases, is managed by specialist clinicians during regular clinic follow-up visits. Patients spend approximately 1 h per year with clinicians, with few provisions made for patient participation in their own management for the remainder of the year, resulting in...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02061.x

    authors: Robinson A

    更新日期:2004-10-01 00:00:00

  • Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease.

    abstract:BACKGROUND:Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but favourable data regarding its possible use in patients with inflammatory bowel disease (IBD). AIMS:To evaluate the efficacy and safety of tacrolimus in patients with IBD...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.15687

    authors: Rodríguez-Lago I,Castro-Poceiro J,Fernández-Clotet A,Mesonero F,López-Sanromán A,López-García A,Márquez L,Clos-Parals A,Cañete F,Vicuña M,Nantes Ó,Merino O,Matallana V,Gordillo J,Elorza A,Vicente R,Casanova MJ,Ferreiro-

    更新日期:2020-05-01 00:00:00

  • The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience.

    abstract:AIM:To asses the efficacy and safety of ciclosporin in a paediatric population with inflammatory bowel disease. PATIENTS AND METHODS:Twenty-three Italian children treated with ciclosporin were studied retrospectively. The indications for treatment were severe unresponsive colitis, chronic active colitis or severe fist...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1046/j.1365-2036.2002.01308.x

    authors: Barabino A,Torrente F,Castellano E,Gandullia P,Calvi A,Cucchiara S,De GL,Fontana M,Lionetti P,De Giacomo C,Gissi A

    更新日期:2002-08-01 00:00:00

  • Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?

    abstract:BACKGROUND:The presence of the gastric pathogen, Helicobacter pylori influences acid suppression by proton pump inhibitors and treatment outcome in patients with gastro-oesophageal reflux disease. AIM:To determine the influence of H. pylori infection on effectiveness of rabeprazole in primary and secondary care patien...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2004.02096.x

    authors: Wit NJ,Boer WA,Geldof H,Hazelhoff B,Bergmans P,Tytgat GN,Smout AJ

    更新日期:2004-08-15 00:00:00

  • Review article: approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions.

    abstract::Despite implementation of screening and surveillance strategies, a significantly large number of patients with Barrett's oesophagus remain undiagnosed. In those who are identified, the management options include acid reduction therapies with proton pump inhibitors or anti-reflux surgery. Endoscopic ablative therapies ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.0953-0673.2004.01839.x

    authors: Jankowski J,Sharma P

    更新日期:2004-02-01 00:00:00

  • Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument.

    abstract:BACKGROUND:While current medications used to treat patients with chronic hepatitis C virus (HCV) effectively produce sustained viral response (SVR), postponement of therapy is often times attributed to patient perceptions of unfavourable outcomes. However, an instrument to assess patient perceptions of therapy (i.e. tr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12202

    authors: Szeinbach SL,Baran RW,Dietz B,Gazzouola Rocca L,Littlefield D,Yawn BP

    更新日期:2013-03-01 00:00:00

  • Review article: platelets in inflammatory bowel disease--pathogenetic role and therapeutic implications.

    abstract::An elevated platelet count is well recognized as a marker of inflammatory bowel disease activity. There is an increased incidence of systemic thromboembolism in this disease. Recent work indicates that platelets exhibit several proinflammatory properties including release of inflammatory mediators, and recruitment, ch...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.1997.153328000.x

    authors: Collins CE,Rampton DS

    更新日期:1997-04-01 00:00:00

  • Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography.

    abstract:BACKGROUND:Data on whether long-acting somatostatin analogue octreotide causes or prevents pancreatic injury following endoscopic retrograde cholangiopancreatography (ERCP) are controversial. AIM:This multicentre, prospective trial studied the effect of octreotide on pancreatic injury in a large unselected group of pa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1998.00414.x

    authors: Tulassay Z,Döbrönte Z,Prónai L,Zágoni T,Juhász L

    更新日期:1998-11-01 00:00:00

  • Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population.

    abstract:BACKGROUND:Gastro-oesophageal reflux disease (GERD) and irritable bowel syndrome may occur more often than expected by chance, but little community data exists and risk factors are unknown. AIM:To determine prevalence and risk factors for overlap of GERD and irritable bowel disease. METHODS:Population-based, cross-se...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2007.03366.x

    authors: Jung HK,Halder S,McNally M,Locke GR 3rd,Schleck CD,Zinsmeister AR,Talley NJ

    更新日期:2007-08-01 00:00:00

  • Systematic review with meta-analysis: liver transplant provides survival benefit in patients with acute on chronic liver failure.

    abstract:BACKGROUND:Data on liver transplantation (LT) in acute on chronic liver failure (ACLF) are scanty. AIM:To perform meta-analysis on outcomes after LT for ACLF compared with ACLF patients not receiving LT or with LT recipients for indications other than ACLF. METHODS:We pooled data from 12 studies on LT outcomes among ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.15793

    authors: Abdallah MA,Waleed M,Bell MG,Nelson M,Wong R,Sundaram V,Singal AK

    更新日期:2020-07-01 00:00:00

  • Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.

    abstract:BACKGROUND:Reliable data on inflammatory biomarkers for predicting relapse of paediatric inflammatory bowel disease (IBD) are lacking. AIM:To investigate the predictive value of faecal calprotectin (FC) and CRP for symptomatic relapse in pediatric IBD in clinical remission. METHODS:In this cross-sectional cohort stud...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13950

    authors: Diederen K,Hoekman DR,Leek A,Wolters VM,Hummel TZ,de Meij TG,Koot BG,Tabbers MM,Benninga MA,Kindermann A

    更新日期:2017-04-01 00:00:00

  • Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer.

    abstract:BACKGROUND:Helicobacter pylori eradication has become the standard treatment for duodenal ulcer. However, there is no relevant evidence for antibacterial treatment of the white scar stage of duodenal ulcer (duodenal ulcer scar) in patients with no past history of duodenal ulcer. AIM:To investigate whether H. pylori er...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2002.01174.x

    authors: Kim JS,Kim SG,Choi IJ,Park MJ,Kim BG,Jung HC,Song IS

    更新日期:2002-02-01 00:00:00

  • Scintigraphic assessment of the intragastric distribution and gastric emptying of an encapsulated drug: the effect of feeding and of a proton pump inhibitor.

    abstract:BACKGROUND:Local delivery of therapeutic agents to the stomach may be a useful strategy in the treatment of Helicobacter pylori infection. We aimed to see whether the intragastric distribution and gastric retention of a therapeutic agent could be improved, either by giving omeprazole or by dosing after a meal. METHODS...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1994.tb00320.x

    authors: Atherton JC,Washington N,Bracewell MA,Sutton LJ,Greaves JL,Perkins AC,Hawkey CJ,Spiller RC

    更新日期:1994-10-01 00:00:00

  • A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.

    abstract:AIM:To assess the efficacy of the 8-week therapy with esomeprazole 40 mg vs. pantoprazole 40 mg for healing erosive oesophagitis (EE) as part of a management study. METHODS:Patients had a history of gastro-oesophageal reflux disease symptoms (> or =6 months) and had suffered heartburn on at least 4 of the 7 days prece...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2005.02368.x

    authors: Labenz J,Armstrong D,Lauritsen K,Katelaris P,Schmidt S,Schütze K,Wallner G,Juergens H,Preiksaitis H,Keeling N,Nauclér E,Eklund S,Expo Study Investigators.

    更新日期:2005-03-15 00:00:00

  • Neurokinin-1 receptor antagonism in a human model of visceral hypersensitivity.

    abstract:BACKGROUND:Substance P acting via the neurokinin-1 receptor is involved in the development of hyperalgesia, although studies using neurokinin-1 receptor antagonists (NK-1RA) in human somatic pain have been disappointing. AIM:To evaluate whether Substance P is involved in the development of human visceral pain/hyperalg...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2006.03190.x

    authors: Willert RP,Hobson AR,Delaney C,Hicks KJ,Dewit OE,Aziz Q

    更新日期:2007-02-01 00:00:00

  • Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry.

    abstract:BACKGROUND:Proton pump inhibitors (PPIs) are the most commonly used first-line therapy for patients with eosinophilic oesophagitis (EoE). However, many aspects related to PPIs in EoE are still unknown. AIMS:To assess the effectiveness of PPI therapy for EoE in real-world practice. METHODS:This cross-sectional study c...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15957

    authors: Laserna-Mendieta EJ,Casabona S,Guagnozzi D,Savarino E,Perelló A,Guardiola-Arévalo A,Barrio J,Pérez-Martínez I,Lund Krarup A,Alcedo J,de la Riva S,Rey-Iborra E,Santander C,Arias Á,Lucendo AJ,EUREOS EoE CONNECT Research group

    更新日期:2020-09-01 00:00:00

  • Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea.

    abstract:BACKGROUND:Irritable bowel syndrome is a widespread disorder with a marked socioeconomic burden. Previous studies support the proposal that a subset of patients with features compatible with diarrhoea-predominant IBS (IBS-D) have bile acid malabsorption (BAM). AIM:To perform a systematic review and meta-analysis to as...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/apt.13227

    authors: Slattery SA,Niaz O,Aziz Q,Ford AC,Farmer AD

    更新日期:2015-07-01 00:00:00

  • Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease.

    abstract:BACKGROUND:Non-alcoholic fatty liver disease affects 10-35% of the adult population worldwide; there is no consensus on its treatment. Omega-3 fatty acids have proven benefits for hyperlipidaemia and cardiovascular disease, and have recently been suggested as a treatment for non-alcoholic fatty liver disease. AIMS:To ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2010.04230.x

    authors: Masterton GS,Plevris JN,Hayes PC

    更新日期:2010-04-01 00:00:00

  • Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.

    abstract:BACKGROUND:For patients with UC, flexible maintenance dosing therapy may confer advantages for safety, efficacy, costs and patient preference. Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. AIM:To assess the efficacy and safety of tofacitinib dose de-escalation and escalation in patients...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.15555

    authors: Sands BE,Armuzzi A,Marshall JK,Lindsay JO,Sandborn WJ,Danese S,Panés J,Bressler B,Colombel JF,Lawendy N,Maller E,Zhang H,Chan G,Salese L,Tsilkos K,Marren A,Su C

    更新日期:2020-01-01 00:00:00

  • The effect of omeprazole on gastric juice viscosity, pH and bacterial counts.

    abstract:BACKGROUND:In vitro studies have shown that pH is an important determinant of mucus structure and function, but the relationship in vivo is unclear. Omeprazole increases intragastric pH and also allows bacterial overgrowth. In this study we have assessed the effect of omeprazole on gastric juice viscosity and examined ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1996.tb00183.x

    authors: Goddard AF,Spiller RC

    更新日期:1996-02-01 00:00:00

  • Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.

    abstract:BACKGROUND:Faecal calprotectin and lactoferrin increasingly serve as surrogate markers of disease activity in IBD. Data on the correlation of these markers with simple endoscopic score for Crohn's disease (SES-CD) and with histological findings are as yet limited. Aim To study the correlation of faecal calprotectin and...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03835.x

    authors: Sipponen T,Kärkkäinen P,Savilahti E,Kolho KL,Nuutinen H,Turunen U,Färkkilä M

    更新日期:2008-11-15 00:00:00

  • Selective COX-2 inhibitors and human inflammatory bowel disease.

    abstract:BACKGROUND:Much recent effort has been made to produce selective inhibitors of cyclo-oxygenase-2 (COX-2) in the belief that these will lack the gastrointestinal damaging effects of traditional non-steroidal anti-inflammatory drugs (NSAIDs). Inflammatory bowel disease is associated with increased local production of pro...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00585.x

    authors: McCartney SA,Mitchell JA,Fairclough PD,Farthing MJ,Warner TD

    更新日期:1999-08-01 00:00:00

  • Antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in patients with obstructive jaundice: is it worth the cost?

    abstract:BACKGROUND:There are few published data concerning the economic impact of antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in the setting of biliary obstruction. AIM:To perform decision analysis to determine the costs of prophylaxis in patients undergoing endoscopic retrograde cholangiopa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2002.01209.x

    authors: Thompson BF,Arguedas MR,Wilcox CM

    更新日期:2002-04-01 00:00:00